Tanaka, Yasuhito
,
Ogawa, Eiichi
Huang, Chung-Feng
Toyoda, Hidenori
Jun, Dae Won
Tseng, Cheng-Hao
Hsu, Yao-Chun
Enomoto, Masaru
Takahashi, Hirokazu
Furusyo, Norihiro
Yeh, Ming-Lun
Iio, Etsuko
Yasuda, Satoshi
Lam, Carla Pui-Mei
Lee, Dong Hyun
Haga, Hiroaki
Yoon, Eileen L.
Ahn, Sang Bong
Wong, Grace
Nakamuta, Makoto
Nomura, Hideyuki
Tsai, Pei-Chien
Jung, Jang Han
Song, Do Seon
Dang, Hansen
Maeda, Mayumi
Henry, Linda
Cheung, Ramsey
Yuen, Man-Fung
Ueno, Yoshiyuki
Eguchi, Yuichiro
Tamori, Akihiro
Yu, Ming-Lung
Hayashi, Jun
Nguyen, Mindie H. http://orcid.org/0000-0002-6275-4989
Funding for this research was provided by:
Gilead Sciences
Kaohsiung Medical University (KMUDK109002, KMU-TC108B07, KMU-TCA04-3)
Article History
Received: 18 August 2020
Accepted: 27 October 2020
First Online: 4 December 2020
Compliance with ethical standards
:
: YT: Research support: Janssen, Gilead, Speaker: Gilead. CFH: Speaker: AbbVie, BMS, Gilead, Merck. YCH: Research support: Gilead, Consultation: Gilead, Speaker: AbbVie, Bristol-Myers Squibb and Gilead. ME: Speaker: AbbVie. DHL: Research support: Gilead Sciences Korea, Korea Pharma. GW: Research support: Gilead, Consultation: Gilead, Speaker: Abbott, AbbVie, BMS, Echosens, Furui, Gilead, Janssen and Roche, Research grant: Gilead. MFY: Consultation: AbbVie, Arbutus Biopharma, Assembly Biosciences, Bristol Myer Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp and Dohme, Clear B Therapeutics, Springbank Pharmaceutical. YU: Research support: Gilead, AbbVie, Governmental funding for research: AMED. YE: Speaker: Gilead. MLY: Research support: Abbott, BMS, Gilead and Merck, Consultant and/or an advisory board: Abbvie, Abbott, Ascletis, BMS, Gilead and Merck, Speaker: Abbvie, Abbott, BMS, Gilead, Merck, and IPSEN. WLC: Consultation: Gilead, AbbVie, BMS, MSD, PharmaEssentia, Speaker: Gilead, AbbVie, BMS, MSD, PharmaEssentia. CYD: Consultation: Abbvie, Speaker: AbbVie, Merck, BMS, and Gilead. MHL: Research support: The Ministry of Science and Technology, Taipei, Taiwan (105-2628-B010-003-MY4, 107-2314-B-010-004-MY2 and 107-2918-I-010-004), Consultation: Gilead. MHN: Research support: Enanta, Gilead, Pfizer, B.K. Kee Foundation, National Cancer Institute. Consultant and/or an advisory board: Novartis, Bayer, Eisai, Intercept, Gilead, Janssen, Laboratory of Advanced Medicine, Exact Sciences, and Intercept. All other authors have nothing to disclose.
: The study was conducted in accordance with the ethics principles of the Declaration of Helsinki in 1975, as revised in 2008, and was approved by the Institutional Review Board of Stanford University, Stanford, California, USA and at each participating study center.